Review



anti mouse cd8α mab  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Bio X Cell anti mouse cd8α mab
    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of <t>CD8</t> + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).
    Anti Mouse Cd8α Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 567 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8α mab/product/Bio X Cell
    Average 97 stars, based on 567 article reviews
    anti mouse cd8α mab - by Bioz Stars, 2026-06
    97/100 stars

    Images

    1) Product Images from "A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer"

    Article Title: A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer

    Journal: Science Advances

    doi: 10.1126/sciadv.aea6734

    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of CD8 + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).
    Figure Legend Snippet: ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of CD8 + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).

    Techniques Used: Flow Cytometry, Staining, Quantitative RT-PCR, Recombinant, Ex Vivo, Control, Two Tailed Test, MANN-WHITNEY

    ( A ) Experimental outline of murine PDAC model. Plat +/+ and Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from Plat +/+ and Plat −/− mice. ( C ) ELISA of tPA in tissue supernatants from pancreata of Plat +/+ mice (no tumor) and orthotopic tumors from Plat +/+ and Plat −/− mice. ( D ) Picrosirius red staining of orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( E ) Co-IF staining for cCasp3 (red), ECAD (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 4 FOV per animal). ( F to H ) Flow cytometry quantification of frequencies of total T cells (F), CD8 + T cells (G), and conventional dendritic cells (H) among live cells in orthotopic tumors. ( I ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (I) represent individual mice. Data are means ± SEM. P values were determined by Mann-Whitney test [(B) and (F)], two-way ANOVA with Holm-Sidak post hoc (C), and two-tailed unpaired t test [(D), (E), and (G) to (I)].
    Figure Legend Snippet: ( A ) Experimental outline of murine PDAC model. Plat +/+ and Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from Plat +/+ and Plat −/− mice. ( C ) ELISA of tPA in tissue supernatants from pancreata of Plat +/+ mice (no tumor) and orthotopic tumors from Plat +/+ and Plat −/− mice. ( D ) Picrosirius red staining of orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( E ) Co-IF staining for cCasp3 (red), ECAD (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 4 FOV per animal). ( F to H ) Flow cytometry quantification of frequencies of total T cells (F), CD8 + T cells (G), and conventional dendritic cells (H) among live cells in orthotopic tumors. ( I ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (I) represent individual mice. Data are means ± SEM. P values were determined by Mann-Whitney test [(B) and (F)], two-way ANOVA with Holm-Sidak post hoc (C), and two-tailed unpaired t test [(D), (E), and (G) to (I)].

    Techniques Used: Enzyme-linked Immunosorbent Assay, Staining, Flow Cytometry, MANN-WHITNEY, Two Tailed Test

    ( A ) Experimental outline of murine PDAC model. WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice. ( C ) IHC staining for CD8 in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). ( D ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (D) represent individual mice. Data are means ± SEM. P values were determined by one-way ANOVA with Holm-Sidak post hoc [(B) to (D)]. ( E ) Working model. Left: Hypoxia stabilizes HIF proteins, inducing PAI1 expression in pancreatic CAFs. Although tPA levels are elevated in PDAC, PAI1 predominantly inhibits its activity, thereby suppressing antitumor immunity. Middle: Elimination of stromal PAI1 restores tPA activity, enhancing antitumor CD8 + T cell responses, accompanied by alleviation of immunosuppressive TAM phenotypes and increased dendritic cell (DC) infiltration. Stromal PAI1-driven tumor growth depends on CD8 + T cells. Right: Removal of stromal tPA abolishes residual tPA activity, further promoting an immunosuppressive TME and tumor growth.
    Figure Legend Snippet: ( A ) Experimental outline of murine PDAC model. WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice. ( C ) IHC staining for CD8 in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). ( D ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (D) represent individual mice. Data are means ± SEM. P values were determined by one-way ANOVA with Holm-Sidak post hoc [(B) to (D)]. ( E ) Working model. Left: Hypoxia stabilizes HIF proteins, inducing PAI1 expression in pancreatic CAFs. Although tPA levels are elevated in PDAC, PAI1 predominantly inhibits its activity, thereby suppressing antitumor immunity. Middle: Elimination of stromal PAI1 restores tPA activity, enhancing antitumor CD8 + T cell responses, accompanied by alleviation of immunosuppressive TAM phenotypes and increased dendritic cell (DC) infiltration. Stromal PAI1-driven tumor growth depends on CD8 + T cells. Right: Removal of stromal tPA abolishes residual tPA activity, further promoting an immunosuppressive TME and tumor growth.

    Techniques Used: Immunohistochemistry, Staining, Expressing, Activity Assay



    Similar Products

    anti mouse cd8α mab  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8α mab
    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of <t>CD8</t> + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).
    Anti Mouse Cd8α Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8α mab/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti mouse cd8α mab - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    anti mouse cd8  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8
    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of <t>CD8</t> + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).
    Anti Mouse Cd8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti mouse cd8 - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    anti cd8α  (Bio X Cell)
    97
    Bio X Cell anti cd8α
    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of <t>CD8</t> + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).
    Anti Cd8α, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd8α/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti cd8α - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    anti mouse cd8α antibody  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8α antibody
    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of <t>CD8</t> + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).
    Anti Mouse Cd8α Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8α antibody/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti mouse cd8α antibody - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    anti mouse cd8a antibodies  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8a antibodies
    HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of <t>CD8a.</t> ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of CD8 + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.
    Anti Mouse Cd8a Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8a antibodies/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti mouse cd8a antibodies - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    anti mouse cd8α  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8α
    HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of <t>CD8</t> + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.
    Anti Mouse Cd8α, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8α/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti mouse cd8α - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    cd8a  (Bio X Cell)
    97
    Bio X Cell cd8a
    HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of <t>CD8</t> + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.
    Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8a/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    cd8a - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    anti mouse cd8 α ab  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8 α ab
    HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of <t>CD8</t> + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.
    Anti Mouse Cd8 α Ab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd8 α ab/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti mouse cd8 α ab - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of CD8 + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).

    Journal: Science Advances

    Article Title: A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer

    doi: 10.1126/sciadv.aea6734

    Figure Lengend Snippet: ( A to I ) Serpine1 +/+ and Serpine1 −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected at day 21. [(A) and (B)] Flow cytometry quantification of frequencies of total T cells (CD45 + CD3 + ) (A) and conventional dendritic cells (CD45 + F4/80 − CD11c + MHCII + ) (B) among live cells in orthotopic tumors. (C) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). (D) Quantitative RT-PCR analysis of Arg1 in BMDMs treated with vehicle or recombinant PAI1 (rPAI1) for 20 hours. Each dot represents individual primary BMDM lines. (E) Flow cytometry quantification of frequency of CD8 + T cells (CD45 + CD3 + CD8 + ) among live cells in orthotopic tumors. [(F) and (G)] Flow cytometry quantification of frequencies and absolute numbers of GZMB + CD8 + T cells (F) and Ki67 + CD8 + T cells (G) following a 5-hour ex vivo PMA/ionomycin stimulation of tumor digests. (H) Co-IF staining for GZMB (green), CD8 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). (I) Co-IF staining for Ki67 (red), CD8 (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( J ) Experimental design for CD8 + T cell depletion. Mice received control immunoglobulin G (IgG) or anti-CD8 antibody twice per week, starting 5 days postimplantation (7940B). Tumors were harvested at day 21. ( K ) Tumor weight of orthotopic tumors with CD8⁺ T cell antibody-mediated depletion. Symbols in (A) to (I) and (K) represent individual mice. Data are means ± SEM. P values were determined by two-tailed unpaired t test [(A), (B), right of (C), (D), (E) to (G), and right of (H)], Mann-Whitney test [left of (C), left of (H), and (I)], and Mann-Whitney test with Holm-Sidak post hoc (K).

    Article Snippet: Depletion of CD8 + T cells were performed starting from 5 days following orthotopic injection of 7940B cells by administration of intraperitoneal injections of 200 μg of anti-mouse CD8α mAb (2.43, no. BE0061, BioXCell) or control isotype antibody (LTF-2, no. BE0090, BioXCell) twice per week for the entire course of the experiments.

    Techniques: Flow Cytometry, Staining, Quantitative RT-PCR, Recombinant, Ex Vivo, Control, Two Tailed Test, MANN-WHITNEY

    ( A ) Experimental outline of murine PDAC model. Plat +/+ and Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from Plat +/+ and Plat −/− mice. ( C ) ELISA of tPA in tissue supernatants from pancreata of Plat +/+ mice (no tumor) and orthotopic tumors from Plat +/+ and Plat −/− mice. ( D ) Picrosirius red staining of orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( E ) Co-IF staining for cCasp3 (red), ECAD (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 4 FOV per animal). ( F to H ) Flow cytometry quantification of frequencies of total T cells (F), CD8 + T cells (G), and conventional dendritic cells (H) among live cells in orthotopic tumors. ( I ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (I) represent individual mice. Data are means ± SEM. P values were determined by Mann-Whitney test [(B) and (F)], two-way ANOVA with Holm-Sidak post hoc (C), and two-tailed unpaired t test [(D), (E), and (G) to (I)].

    Journal: Science Advances

    Article Title: A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer

    doi: 10.1126/sciadv.aea6734

    Figure Lengend Snippet: ( A ) Experimental outline of murine PDAC model. Plat +/+ and Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from Plat +/+ and Plat −/− mice. ( C ) ELISA of tPA in tissue supernatants from pancreata of Plat +/+ mice (no tumor) and orthotopic tumors from Plat +/+ and Plat −/− mice. ( D ) Picrosirius red staining of orthotopic tumors, and corresponding quantification ( n = 5 FOV per animal). ( E ) Co-IF staining for cCasp3 (red), ECAD (green), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 4 FOV per animal). ( F to H ) Flow cytometry quantification of frequencies of total T cells (F), CD8 + T cells (G), and conventional dendritic cells (H) among live cells in orthotopic tumors. ( I ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (I) represent individual mice. Data are means ± SEM. P values were determined by Mann-Whitney test [(B) and (F)], two-way ANOVA with Holm-Sidak post hoc (C), and two-tailed unpaired t test [(D), (E), and (G) to (I)].

    Article Snippet: Depletion of CD8 + T cells were performed starting from 5 days following orthotopic injection of 7940B cells by administration of intraperitoneal injections of 200 μg of anti-mouse CD8α mAb (2.43, no. BE0061, BioXCell) or control isotype antibody (LTF-2, no. BE0090, BioXCell) twice per week for the entire course of the experiments.

    Techniques: Enzyme-linked Immunosorbent Assay, Staining, Flow Cytometry, MANN-WHITNEY, Two Tailed Test

    ( A ) Experimental outline of murine PDAC model. WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice. ( C ) IHC staining for CD8 in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). ( D ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (D) represent individual mice. Data are means ± SEM. P values were determined by one-way ANOVA with Holm-Sidak post hoc [(B) to (D)]. ( E ) Working model. Left: Hypoxia stabilizes HIF proteins, inducing PAI1 expression in pancreatic CAFs. Although tPA levels are elevated in PDAC, PAI1 predominantly inhibits its activity, thereby suppressing antitumor immunity. Middle: Elimination of stromal PAI1 restores tPA activity, enhancing antitumor CD8 + T cell responses, accompanied by alleviation of immunosuppressive TAM phenotypes and increased dendritic cell (DC) infiltration. Stromal PAI1-driven tumor growth depends on CD8 + T cells. Right: Removal of stromal tPA abolishes residual tPA activity, further promoting an immunosuppressive TME and tumor growth.

    Journal: Science Advances

    Article Title: A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer

    doi: 10.1126/sciadv.aea6734

    Figure Lengend Snippet: ( A ) Experimental outline of murine PDAC model. WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice were orthotopically implanted with pancreatic cancer cells (7940B), and tumors were collected 21 days postimplantation. ( B ) Tumor weight of orthotopic tumors harvested from WT, Serpine1 −/− , and Serpine1 −/− ; Plat −/− mice. ( C ) IHC staining for CD8 in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). ( D ) Co-IF staining for Arg1 (green), F4/80 (red), and DAPI (blue) in orthotopic tumors, and corresponding quantification ( n = 3 FOV per animal). Symbols in (B) to (D) represent individual mice. Data are means ± SEM. P values were determined by one-way ANOVA with Holm-Sidak post hoc [(B) to (D)]. ( E ) Working model. Left: Hypoxia stabilizes HIF proteins, inducing PAI1 expression in pancreatic CAFs. Although tPA levels are elevated in PDAC, PAI1 predominantly inhibits its activity, thereby suppressing antitumor immunity. Middle: Elimination of stromal PAI1 restores tPA activity, enhancing antitumor CD8 + T cell responses, accompanied by alleviation of immunosuppressive TAM phenotypes and increased dendritic cell (DC) infiltration. Stromal PAI1-driven tumor growth depends on CD8 + T cells. Right: Removal of stromal tPA abolishes residual tPA activity, further promoting an immunosuppressive TME and tumor growth.

    Article Snippet: Depletion of CD8 + T cells were performed starting from 5 days following orthotopic injection of 7940B cells by administration of intraperitoneal injections of 200 μg of anti-mouse CD8α mAb (2.43, no. BE0061, BioXCell) or control isotype antibody (LTF-2, no. BE0090, BioXCell) twice per week for the entire course of the experiments.

    Techniques: Immunohistochemistry, Staining, Expressing, Activity Assay

    HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of CD8 + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of CD8 + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.

    Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

    Techniques: Quantitative RT-PCR, Comparison

    ( A – D ) B16-F10 tumor-bearing mice (s.c.) were intratumorally dosed with DNA-LNP at days 0 and 3. Tumors were collected at day 7 and analyzed using flow cytometry. ( A ) Numbers of indicated immune cells per milligram of tumor tissues. ( B ) CD4/CD8 ratio. ( C ) Percentage of Granzyme B + cells and ( D ) CD69 + cells from CD8 + T cells or NK cells. ( E and F ) Mice with B16-F10 lung metastasis were i.v. dosed at days 0, 3, and 6, and lung sections were analyzed at day 13 by CD8 IHC. ( E ) Representative images of lung sections and ( F ) quantification of CD8 + cells. Min-to-max whiskers are shown in the box and whiskers plot. Data shown as mean ± SD. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: ( A – D ) B16-F10 tumor-bearing mice (s.c.) were intratumorally dosed with DNA-LNP at days 0 and 3. Tumors were collected at day 7 and analyzed using flow cytometry. ( A ) Numbers of indicated immune cells per milligram of tumor tissues. ( B ) CD4/CD8 ratio. ( C ) Percentage of Granzyme B + cells and ( D ) CD69 + cells from CD8 + T cells or NK cells. ( E and F ) Mice with B16-F10 lung metastasis were i.v. dosed at days 0, 3, and 6, and lung sections were analyzed at day 13 by CD8 IHC. ( E ) Representative images of lung sections and ( F ) quantification of CD8 + cells. Min-to-max whiskers are shown in the box and whiskers plot. Data shown as mean ± SD. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

    Techniques: Flow Cytometry, Comparison

    HDTVI-induced HCC-bearing mice ( n = 11) received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Mice received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at days –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Tumor growth indicated by serum GLuc activity. ( B ) Survival curves. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, *** P < 0.001, and ns (not significant).

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: HDTVI-induced HCC-bearing mice ( n = 11) received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Mice received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at days –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Tumor growth indicated by serum GLuc activity. ( B ) Survival curves. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, *** P < 0.001, and ns (not significant).

    Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

    Techniques: Activity Assay

    Mouse tumor models received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at day –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Survival curves of C1498 AML tumor-bearing mice ( n = 8) after i.v. administration of 5 μg of DNA-LNP at days 0, 3, and 6. ( B ) Tumor growth curves and ( C ) survival curves of B16-F10 tumor-bearing mice ( n = 7) after intratumoral administration of 10 μg of DNA-LNP at days 0, 3, and 6. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, *** P < 0.001, and ns (not significant).

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: Mouse tumor models received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at day –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Survival curves of C1498 AML tumor-bearing mice ( n = 8) after i.v. administration of 5 μg of DNA-LNP at days 0, 3, and 6. ( B ) Tumor growth curves and ( C ) survival curves of B16-F10 tumor-bearing mice ( n = 7) after intratumoral administration of 10 μg of DNA-LNP at days 0, 3, and 6. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, *** P < 0.001, and ns (not significant).

    Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

    Techniques:

    HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of CD8 + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of CD8 + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.

    Article Snippet: The following dosing materials were purchased for the study: ADU-S100 from MedChemExpress and InVivoMAb rat IgG2a isotype control (BE0089, clone 2A3), anti-mouse CD8α (BE0061, clone 2.43), anti-mouse NK1.1 (BE0036, clone PK136), and anti-mouse PD-L1 (BE0101, clone 10F.9G2) from BioXCell.

    Techniques: Quantitative RT-PCR, Comparison

    ( A – D ) B16-F10 tumor-bearing mice (s.c.) were intratumorally dosed with DNA-LNP at days 0 and 3. Tumors were collected at day 7 and analyzed using flow cytometry. ( A ) Numbers of indicated immune cells per milligram of tumor tissues. ( B ) CD4/CD8 ratio. ( C ) Percentage of Granzyme B + cells and ( D ) CD69 + cells from CD8 + T cells or NK cells. ( E and F ) Mice with B16-F10 lung metastasis were i.v. dosed at days 0, 3, and 6, and lung sections were analyzed at day 13 by CD8 IHC. ( E ) Representative images of lung sections and ( F ) quantification of CD8 + cells. Min-to-max whiskers are shown in the box and whiskers plot. Data shown as mean ± SD. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: ( A – D ) B16-F10 tumor-bearing mice (s.c.) were intratumorally dosed with DNA-LNP at days 0 and 3. Tumors were collected at day 7 and analyzed using flow cytometry. ( A ) Numbers of indicated immune cells per milligram of tumor tissues. ( B ) CD4/CD8 ratio. ( C ) Percentage of Granzyme B + cells and ( D ) CD69 + cells from CD8 + T cells or NK cells. ( E and F ) Mice with B16-F10 lung metastasis were i.v. dosed at days 0, 3, and 6, and lung sections were analyzed at day 13 by CD8 IHC. ( E ) Representative images of lung sections and ( F ) quantification of CD8 + cells. Min-to-max whiskers are shown in the box and whiskers plot. Data shown as mean ± SD. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Article Snippet: The following dosing materials were purchased for the study: ADU-S100 from MedChemExpress and InVivoMAb rat IgG2a isotype control (BE0089, clone 2A3), anti-mouse CD8α (BE0061, clone 2.43), anti-mouse NK1.1 (BE0036, clone PK136), and anti-mouse PD-L1 (BE0101, clone 10F.9G2) from BioXCell.

    Techniques: Flow Cytometry, Comparison

    HDTVI-induced HCC-bearing mice ( n = 11) received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Mice received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at days –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Tumor growth indicated by serum GLuc activity. ( B ) Survival curves. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, *** P < 0.001, and ns (not significant).

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: HDTVI-induced HCC-bearing mice ( n = 11) received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Mice received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at days –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Tumor growth indicated by serum GLuc activity. ( B ) Survival curves. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, *** P < 0.001, and ns (not significant).

    Article Snippet: The following dosing materials were purchased for the study: ADU-S100 from MedChemExpress and InVivoMAb rat IgG2a isotype control (BE0089, clone 2A3), anti-mouse CD8α (BE0061, clone 2.43), anti-mouse NK1.1 (BE0036, clone PK136), and anti-mouse PD-L1 (BE0101, clone 10F.9G2) from BioXCell.

    Techniques: Activity Assay

    Mouse tumor models received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at day –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Survival curves of C1498 AML tumor-bearing mice ( n = 8) after i.v. administration of 5 μg of DNA-LNP at days 0, 3, and 6. ( B ) Tumor growth curves and ( C ) survival curves of B16-F10 tumor-bearing mice ( n = 7) after intratumoral administration of 10 μg of DNA-LNP at days 0, 3, and 6. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, *** P < 0.001, and ns (not significant).

    Journal: JCI Insight

    Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

    doi: 10.1172/jci.insight.197404

    Figure Lengend Snippet: Mouse tumor models received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at day –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Survival curves of C1498 AML tumor-bearing mice ( n = 8) after i.v. administration of 5 μg of DNA-LNP at days 0, 3, and 6. ( B ) Tumor growth curves and ( C ) survival curves of B16-F10 tumor-bearing mice ( n = 7) after intratumoral administration of 10 μg of DNA-LNP at days 0, 3, and 6. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, *** P < 0.001, and ns (not significant).

    Article Snippet: The following dosing materials were purchased for the study: ADU-S100 from MedChemExpress and InVivoMAb rat IgG2a isotype control (BE0089, clone 2A3), anti-mouse CD8α (BE0061, clone 2.43), anti-mouse NK1.1 (BE0036, clone PK136), and anti-mouse PD-L1 (BE0101, clone 10F.9G2) from BioXCell.

    Techniques: